Limitations, agreements, and source contact

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · Source last updated 2025-09-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

clinicaltrials@menarinistemline.com

organization

Stemline Therapeutics, Inc.

phone

+1-877-332-7967

title

Carlos A. Garay, MD, Senior Vice President, Clinical Development & Medical Affairs - Solid Tumors

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice